IFATS collection

In vivo therapeutic potential of human adipose tissue mesenchymal stem cells after transplantation into mice with liver injury

Agnieszka Banas, Takumi Teratani, Yusuke Yamamoto, Makoto Tokuhara, Fumitaka Takeshita, Mitsuhiko Osaki, Masaki Kawamata, Takashi Kato, Hitoshi Okochi, Takahiro Ochiya

    Research output: Contribution to journalArticle

    215 Citations (Scopus)

    Abstract

    Mesenchymal stem cells (MSCs), largely present in the adult human body, represent an attractive tool for the establishment of a stem cell-based therapy for liver diseases. Recently, the therapeutic potential and immunomodulatory activity of MSCs have been revealed. Adipose tissue-derived mesenchymal stem cells (AT-MSCs), so-called adipose-derived stem cells or adipose stromal cells, because of their high accessibility with minimal invasiveness, are especially attractive in the context of future clinical applications. The goal of the present study was to evaluate the therapeutic potential of AT-MSCs by their transplantation into nude mice with CCl4-caused liver injury. We observed that after transplantation, AT-MSCs can improve liver functions, which we verified by changes in the levels of biochemical parameters. Ammonia, uric acid, glutamic-pyruvic transaminase, and glutamic-oxaloacetic transaminase concentrations returned to a nearly normal level after AT-MSC transplantation. These results raised the question of how AT-MSCs can achieve this. To discover the possible mechanisms involved in this therapeutic ability of AT-MSCs, in vitro production of cytokines and growth factors was analyzed and compared with MSCs from bone marrow (BM-MSCs) and normal human dermal fibroblasts (NHDFs). As a result we observed that AT-MSCs secrete interleukin 1 receptor α (IL-1Rα), IL-6, IL-8, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), monocyte chemotactic protein 1, nerve growth factor, and hepatocyte growth factor in a volume higher than both BMMSCs and NHDFs. Thus, our findings suggest that ATMSCs may account for their broad therapeutic efficacy in animal models of liver diseases and in the clinical settings for liver disease treatment.

    Original languageEnglish
    Pages (from-to)2705-2712
    Number of pages8
    JournalStem Cells
    Volume26
    Issue number10
    DOIs
    Publication statusPublished - 2008 Oct

    Fingerprint

    Mesenchymal Stem Cell Transplantation
    Mesenchymal Stromal Cells
    Adipose Tissue
    Liver
    Wounds and Injuries
    Liver Diseases
    Therapeutics
    Stem Cells
    Fibroblasts
    Skin
    Interleukin-1 Receptors
    Hepatocyte Growth Factor
    Chemokine CCL2
    Nerve Growth Factor
    Granulocyte Colony-Stimulating Factor
    Granulocyte-Macrophage Colony-Stimulating Factor
    Stromal Cells
    Cell- and Tissue-Based Therapy
    Aspartate Aminotransferases
    Uric Acid

    Keywords

    • Adipose
    • Liver function
    • Liver regeneration
    • Mesenchymal stem cells

    ASJC Scopus subject areas

    • Cell Biology
    • Developmental Biology
    • Molecular Medicine

    Cite this

    IFATS collection : In vivo therapeutic potential of human adipose tissue mesenchymal stem cells after transplantation into mice with liver injury. / Banas, Agnieszka; Teratani, Takumi; Yamamoto, Yusuke; Tokuhara, Makoto; Takeshita, Fumitaka; Osaki, Mitsuhiko; Kawamata, Masaki; Kato, Takashi; Okochi, Hitoshi; Ochiya, Takahiro.

    In: Stem Cells, Vol. 26, No. 10, 10.2008, p. 2705-2712.

    Research output: Contribution to journalArticle

    Banas, A, Teratani, T, Yamamoto, Y, Tokuhara, M, Takeshita, F, Osaki, M, Kawamata, M, Kato, T, Okochi, H & Ochiya, T 2008, 'IFATS collection: In vivo therapeutic potential of human adipose tissue mesenchymal stem cells after transplantation into mice with liver injury', Stem Cells, vol. 26, no. 10, pp. 2705-2712. https://doi.org/10.1634/stemcells.2008-0034
    Banas, Agnieszka ; Teratani, Takumi ; Yamamoto, Yusuke ; Tokuhara, Makoto ; Takeshita, Fumitaka ; Osaki, Mitsuhiko ; Kawamata, Masaki ; Kato, Takashi ; Okochi, Hitoshi ; Ochiya, Takahiro. / IFATS collection : In vivo therapeutic potential of human adipose tissue mesenchymal stem cells after transplantation into mice with liver injury. In: Stem Cells. 2008 ; Vol. 26, No. 10. pp. 2705-2712.
    @article{7247d44f222c47799fcd6081e8d1681a,
    title = "IFATS collection: In vivo therapeutic potential of human adipose tissue mesenchymal stem cells after transplantation into mice with liver injury",
    abstract = "Mesenchymal stem cells (MSCs), largely present in the adult human body, represent an attractive tool for the establishment of a stem cell-based therapy for liver diseases. Recently, the therapeutic potential and immunomodulatory activity of MSCs have been revealed. Adipose tissue-derived mesenchymal stem cells (AT-MSCs), so-called adipose-derived stem cells or adipose stromal cells, because of their high accessibility with minimal invasiveness, are especially attractive in the context of future clinical applications. The goal of the present study was to evaluate the therapeutic potential of AT-MSCs by their transplantation into nude mice with CCl4-caused liver injury. We observed that after transplantation, AT-MSCs can improve liver functions, which we verified by changes in the levels of biochemical parameters. Ammonia, uric acid, glutamic-pyruvic transaminase, and glutamic-oxaloacetic transaminase concentrations returned to a nearly normal level after AT-MSC transplantation. These results raised the question of how AT-MSCs can achieve this. To discover the possible mechanisms involved in this therapeutic ability of AT-MSCs, in vitro production of cytokines and growth factors was analyzed and compared with MSCs from bone marrow (BM-MSCs) and normal human dermal fibroblasts (NHDFs). As a result we observed that AT-MSCs secrete interleukin 1 receptor α (IL-1Rα), IL-6, IL-8, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), monocyte chemotactic protein 1, nerve growth factor, and hepatocyte growth factor in a volume higher than both BMMSCs and NHDFs. Thus, our findings suggest that ATMSCs may account for their broad therapeutic efficacy in animal models of liver diseases and in the clinical settings for liver disease treatment.",
    keywords = "Adipose, Liver function, Liver regeneration, Mesenchymal stem cells",
    author = "Agnieszka Banas and Takumi Teratani and Yusuke Yamamoto and Makoto Tokuhara and Fumitaka Takeshita and Mitsuhiko Osaki and Masaki Kawamata and Takashi Kato and Hitoshi Okochi and Takahiro Ochiya",
    year = "2008",
    month = "10",
    doi = "10.1634/stemcells.2008-0034",
    language = "English",
    volume = "26",
    pages = "2705--2712",
    journal = "Stem Cells",
    issn = "1066-5099",
    publisher = "AlphaMed Press",
    number = "10",

    }

    TY - JOUR

    T1 - IFATS collection

    T2 - In vivo therapeutic potential of human adipose tissue mesenchymal stem cells after transplantation into mice with liver injury

    AU - Banas, Agnieszka

    AU - Teratani, Takumi

    AU - Yamamoto, Yusuke

    AU - Tokuhara, Makoto

    AU - Takeshita, Fumitaka

    AU - Osaki, Mitsuhiko

    AU - Kawamata, Masaki

    AU - Kato, Takashi

    AU - Okochi, Hitoshi

    AU - Ochiya, Takahiro

    PY - 2008/10

    Y1 - 2008/10

    N2 - Mesenchymal stem cells (MSCs), largely present in the adult human body, represent an attractive tool for the establishment of a stem cell-based therapy for liver diseases. Recently, the therapeutic potential and immunomodulatory activity of MSCs have been revealed. Adipose tissue-derived mesenchymal stem cells (AT-MSCs), so-called adipose-derived stem cells or adipose stromal cells, because of their high accessibility with minimal invasiveness, are especially attractive in the context of future clinical applications. The goal of the present study was to evaluate the therapeutic potential of AT-MSCs by their transplantation into nude mice with CCl4-caused liver injury. We observed that after transplantation, AT-MSCs can improve liver functions, which we verified by changes in the levels of biochemical parameters. Ammonia, uric acid, glutamic-pyruvic transaminase, and glutamic-oxaloacetic transaminase concentrations returned to a nearly normal level after AT-MSC transplantation. These results raised the question of how AT-MSCs can achieve this. To discover the possible mechanisms involved in this therapeutic ability of AT-MSCs, in vitro production of cytokines and growth factors was analyzed and compared with MSCs from bone marrow (BM-MSCs) and normal human dermal fibroblasts (NHDFs). As a result we observed that AT-MSCs secrete interleukin 1 receptor α (IL-1Rα), IL-6, IL-8, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), monocyte chemotactic protein 1, nerve growth factor, and hepatocyte growth factor in a volume higher than both BMMSCs and NHDFs. Thus, our findings suggest that ATMSCs may account for their broad therapeutic efficacy in animal models of liver diseases and in the clinical settings for liver disease treatment.

    AB - Mesenchymal stem cells (MSCs), largely present in the adult human body, represent an attractive tool for the establishment of a stem cell-based therapy for liver diseases. Recently, the therapeutic potential and immunomodulatory activity of MSCs have been revealed. Adipose tissue-derived mesenchymal stem cells (AT-MSCs), so-called adipose-derived stem cells or adipose stromal cells, because of their high accessibility with minimal invasiveness, are especially attractive in the context of future clinical applications. The goal of the present study was to evaluate the therapeutic potential of AT-MSCs by their transplantation into nude mice with CCl4-caused liver injury. We observed that after transplantation, AT-MSCs can improve liver functions, which we verified by changes in the levels of biochemical parameters. Ammonia, uric acid, glutamic-pyruvic transaminase, and glutamic-oxaloacetic transaminase concentrations returned to a nearly normal level after AT-MSC transplantation. These results raised the question of how AT-MSCs can achieve this. To discover the possible mechanisms involved in this therapeutic ability of AT-MSCs, in vitro production of cytokines and growth factors was analyzed and compared with MSCs from bone marrow (BM-MSCs) and normal human dermal fibroblasts (NHDFs). As a result we observed that AT-MSCs secrete interleukin 1 receptor α (IL-1Rα), IL-6, IL-8, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), monocyte chemotactic protein 1, nerve growth factor, and hepatocyte growth factor in a volume higher than both BMMSCs and NHDFs. Thus, our findings suggest that ATMSCs may account for their broad therapeutic efficacy in animal models of liver diseases and in the clinical settings for liver disease treatment.

    KW - Adipose

    KW - Liver function

    KW - Liver regeneration

    KW - Mesenchymal stem cells

    UR - http://www.scopus.com/inward/record.url?scp=53949120786&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=53949120786&partnerID=8YFLogxK

    U2 - 10.1634/stemcells.2008-0034

    DO - 10.1634/stemcells.2008-0034

    M3 - Article

    VL - 26

    SP - 2705

    EP - 2712

    JO - Stem Cells

    JF - Stem Cells

    SN - 1066-5099

    IS - 10

    ER -